CGEN

Compugen Ltd.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Ltd. (CGEN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (C). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.4 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 5.5
EV / EBITDA 2.1
Rev Growth YoY 107.0%
Gross Margin 86.9%
Price Return 3M -16.4%
Price Return 12M 29.0%
Catalyst Signal 0.00
Market Cap $198.0M
TTM Revenue $74.0M
Price / Sales 2.7
ROE 50.6%

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B (3.4) C+ (2.5) B- (3.0) C (2.4) C+ (2.6) C+ (2.8)
2026-11-04 B (3.4) C (2.5) B- (2.9) C+ (2.7) C+ (2.7) C+ (2.8)
2026-10-28 B (3.4) C (2.5) B- (2.9) C (2.5) C+ (2.7) C+ (2.8)
2026-10-21 B (3.4) C (2.5) B- (3.0) C (2.4) C+ (2.6) C+ (2.8)
2026-10-14 B (3.4) C (2.5) B- (3.0) C (2.4) C+ (2.6) C+ (2.8)
Page 1 of 4